Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025)

Roivant Sciences has reported Current Deferred Revenue for 5 years, with the latest figure at $1.2 million in Q1 2025.

• For the quarter ending Q1 2025, Current Deferred Revenue fell 71.98% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2025 stood at $1.2 million (down 71.98% YoY), and the FY2025 full-year result was $1.2 million, down 71.98% from the prior year.
• Current Deferred Revenue for Q1 2025 stood at $1.2 million, down from $3.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $12.4 million in Q1 2023, with the low at $1.2 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $6.4 million across 5 years, with a median of $5.9 million in 2021.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 71.46% — and 2024, when it plunged 74.83%.
• Roivant Sciences' Current Deferred Revenue stood at $5.9 million in 2021, then jumped by 31.73% to $7.8 million in 2022, then tumbled by 39.78% to $4.7 million in 2023, then sank by 35.31% to $3.0 million in 2024, then plunged by 61.54% to $1.2 million in 2025.
• The last three Current Deferred Revenue figures came in at $1.2 million (Q1 2025), $3.0 million (Q4 2024), and $3.4 million (Q3 2024), per Business Quant data.